Company intelligence / Profile preview
Evelo Biosciences
Cambridge, Massachusetts, United Statesevelotx.com ↗
- Ownership
- Public · EVLO
- Employees
- ~66
- Development stage
- Other
01
Overview
Evelo Biosciences was developing orally delivered medicines targeting the small intestinal axis for inflammatory diseases. The company faced multiple clinical failures, including EDP1815 for atopic dermatitis in February 2023 and EDP2939 for psoriasis in October 2023. By November 2023, the company had run out of cash and filed for dissolution.
- Therapeutic areas
- OncologyImmunologyDermatologyPulmonology
- Modalities
- Live biotherapeutic productsbacterial extracellular vesicles (EVs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $1.9K
- Total revenue
- $0
- Enterprise value
- $16.7M
Beyond the preview
Go deeper on Evelo Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evelo Biosciences.